Trial · NCT03810703

Differential Responses to Drugs and Sweet Tastes

NCT03810703, Phase 1, Completed, University of Chicago; results first posted 2023-02-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Differential Responses to Drugs and Sweet Tastes. Trials, record NCT03810703. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03810703

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Differential Responses to Drugs and Sweet Tastes
NCT number: NCT03810703
Status: Completed
Phases: Phase 1
Enrollment: 93 participants, actual
Lead sponsor: University of Chicago
Conditions: Bipolar II Disorder
Interventions: Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule
First posted: 2019-01-22
Last updated: 2023-02-22
Results first posted: 2023-02-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ).	End of study (Baseline - time 0 and approximately 4 weeks later)	Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	End of study (Baseline - time 0 and approximately 4 weeks later)		score on a scale	MEAN

Source ClinicalTrials.gov

Results by group15

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Placebo Arm	Feel	18.88	Standard Error 8.84	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Amphetamine 10 mg Arm	Feel	35.25	Standard Error 4.46	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Amphetamine 20 mg Arm	Feel	45.75	Standard Error 8.23	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Placebo Arm	Like	37.44	Standard Error 7.64	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Amphetamine 10 mg Arm	Like	50.69	Standard Error 7.82	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Amphetamine 20 mg Arm	Like	52.81	Standard Error 8.96	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Placebo Arm	Dislike	19.00	Standard Error 5.96	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Amphetamine 10 mg Arm	Dislike	27.19	Standard Error 6.47	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Amphetamine 20 mg Arm	Dislike	16.25	Standard Error 5.15	score on a scale
Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ).	Placebo Arm	High	17.50	Standard Error 5.50	score on a scale

1 to 10 of 15Source ClinicalTrials.gov

See all 15 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo Arm	31
Overall Study	STARTED	Amphetamine 10 mg Arm	31
Overall Study	STARTED	Amphetamine 20 mg Arm	31
Overall Study	COMPLETED	Placebo Arm	31
Overall Study	COMPLETED	Amphetamine 10 mg Arm	31
Overall Study	COMPLETED	Amphetamine 20 mg Arm	31
Overall Study	NOT COMPLETED	Placebo Arm	0
Overall Study	NOT COMPLETED	Amphetamine 10 mg Arm	0
Overall Study	NOT COMPLETED	Amphetamine 20 mg Arm	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals9

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Placebo Arm	31
Total, all-cause mortality	Amphetamine 10 mg Arm	31
Total, all-cause mortality	Amphetamine 20 mg Arm	31
Total, other adverse events	Placebo Arm	31
Total, other adverse events	Amphetamine 10 mg Arm	31
Total, other adverse events	Amphetamine 20 mg Arm	31
Total, serious adverse events	Placebo Arm	31
Total, serious adverse events	Amphetamine 10 mg Arm	31
Total, serious adverse events	Amphetamine 20 mg Arm	31

Source ClinicalTrials.gov

Papers21

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
1637253	BACKGROUND	PubMed
2100356	BACKGROUND	PubMed
2232018	BACKGROUND	PubMed
5908477	BACKGROUND	PubMed
6779335	BACKGROUND	PubMed
9107147	BACKGROUND	PubMed
11597066	BACKGROUND	PubMed
12213517	BACKGROUND	PubMed
12505821	BACKGROUND	PubMed
12716245	BACKGROUND	PubMed

1 to 10 of 21

See all 21 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03810703

GET https://conductscience.org/api/trials/v1/NCT03810703/papers?page=2

API reference For AI assistants